Trials / Completed
CompletedNCT04116203
Dietary Fish Oil Intervention in Polycystic Ovary Syndrome (PCOS)
Dietary Fish Oil Intervention in Polycystic Ovary Syndrome
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- University of Alberta · Academic / Other
- Sex
- Female
- Age
- 18 Years – 30 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective in this proposed study is to determine the effect of dietary fish oil supplementation compared to standard care metformin treatment, and fish oil in combination with metformin on plasma lipids and apoB-remnant lipoprotein metabolism in overweight-obese young women with PCOS.
Detailed description
Specific Objectives; 1. To determine the effect of dietary fish oil supplementation, metformin, and fish oil in combination with metformin on fasting and non-fasting plasma TG, apoB48 and apoB100-lipoprotein concentrations. 2. To determine the physiological mechanisms associated with the effect of dietary fish oil supplementation and metformin on in vivo plasma lipid and apoB-lipoprotein kinetics. We will quantitate the in vivo production and kinetics of plasma TG, apoB48 and apoB100-lipoproteins in plasma and isolated lipoprotein fractions, using established methods. 3. To explore the effects of dietary fish oil supplementation, metformin and fish oil in combination with metformin, on plasma insulin and testosterone, and the association with changes in plasma lipids and apoB-lipoprotein metabolism.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Metformin | Manufacturer's standard 500 mg. Submission Control No.:128147 |
| COMBINATION_PRODUCT | Fish Oil and Metformin | Combo of 2 other arms |
| DIETARY_SUPPLEMENT | Fish Oil | NPN: 80028808 Licence Holder: WN Pharmaceuticals Ltd Dosage Form: Capsule, soft Recommended Route of Administration: Oral |
Timeline
- Start date
- 2016-06-30
- Primary completion
- 2020-11-12
- Completion
- 2020-11-12
- First posted
- 2019-10-04
- Last updated
- 2025-02-28
Locations
2 sites across 1 country: Canada
Source: ClinicalTrials.gov record NCT04116203. Inclusion in this directory is not an endorsement.